Venus Medtech announced today that surgeons in China completed the first implants of its transcatheter aortic valve replacement (TAVR) system. The first implant of its Venus-Vitae TAVR system follows the June implants of the VenusP transcatheter pulmonic valve replacement (TPVR) system. Hangzhou, China-based Venus Medtech developed its next-generation, balloon-expandable, dry-tissue TAVR system in-house. Prof. So […]
Venus Medtech
Venus Medtech touts first implants of transcatheter pulmonic valve replacement system
Venus Medtech announced today that study investigators completed the first implant of its transcatheter pulmonic valve replacement (TPVR) system. A University of Virginia School of Medicine team completed the first implant in the PROTEUS FDA investigational device exemption (IDE) pivotal trial. Investigators reported a smooth procedure in a teenage patient with free pulmonary insufficiency. The […]
Venus Medtech acquires mitral, tricuspid valve replacement company Cardiovalve
Venus Medtech announced that it acquired Cardiovalve and its transcatheter mitral and tricuspid valve treatment technology. Hangzhou, China-based Venus Medtech will acquire 100% equity interest and corresponding equity at a consideration of $300 million, with payments of the consideration coming in installments subject to the completion of certain milestones. According to a news release, Venus […]
Keystone Heart inks distribution agreement with Vasorum
Keystone Heart has started distributing Ireland-based Vasorum’s Celt ACD vascular closure device in the U.S. and Europe, effective this month. Approved by FDA in 2016, the Celt ACT is a biocompatible implant meant to close femoral artery punctures taking place after catheterization. Health providers have implanted the CeltACT in more than 40,000 patients to date. […]
Venus Medtech completes Keystone Heart merger
Chinese transcatheter heart valve maker Venus Medtech said today that it closed its merger with Keystone Heart. Privately-held Keystone Heart sells TriGuard embolic protection devices that are designed to protect the brain during transcatheter aortic valve replacement and other cardiac procedures. Hoping for FDA approval in the third quarter of 2019, Keystone Heart is enrolling patients […]
Venus Medtech to acquire Keystone Heart
Chinese heart valve maker Venus Medtech said today it inked a deal to acquire cerebral embolic protection device maker Keystone Heart for an undisclosed amount. Tampa, Fla.-based Keystone Heart developed and produces TriGuard embolic protection devices, which are designed to protect the brain from emboli during transcatheter aortic valve replacement and other heart procedures to reduce […]
Venus Medtech launches Venus pulmonary valve implant
Chinese heart valve maker Venus Medtech said today it launched its Venus P-Valve self-expanding pulmonary valve implant in Canada, touting that the first procedures with the valve have been performed in the region. The Venus P-Valve was designed for percutaneous use in native right ventricular outflow tracts, the Hangzhou-baesd company said, and is intended for patients who […]
Venus Medtech inks exclusive TriGuard 3 deal with Keystone Heart
Chinese heart valve maker Venus Medtech said yesterday it inked a partnership deal with Keystone Heart through which Venus will gain exclusive rights to develop and sell a third-gen version of Keystone’s TriGuard 3 device in China and other Asian markets. The deal builds on a partnership between the two companies announced last March to promote Venus’ […]
Venus Medtech wins backing from DCP Capital
Chinese heart valve maker Venus Medtech said yesterday it inked a definitive investment agreement with DCP Capital to support the upgrading and internationalization of its valve products. Through the deal, DCP Capital will also support clinical research into a new mitral and tricuspid valve disease treatment technology as the company looks to make a more solid entry into […]
China’s Venus Medtech snaps up TAVR device developer InterValve
Chinese heart valve maker Venus Medtech said today it acquired U.S.-based transcatheter aortic valve replacement device developer InterValve for an undisclosed amount. Intervalve produces the V8 and TAV8 aortic valvuloplasty balloon catheters designed for performing percutaneous balloon angioplasty procedures and for pre and post-dilation during TAVR procedures. Venus said that the shape of the balloon helps […]
Venus Medtech wins Chinese FDA approval for Venus A-valve TAVR
Chinese heart valve maker Venus Medtech said today it won China FDA approval for its Venus A-valve device, touting it as the 1st transcatheter aortic valve implantation device to win CFDA approval. The Venus A-valve device offers a less invasive treatment solution for inoperable and high-risk patients, providing a solution to patients in the region that previously was unavailable, […]
